世界のエルビテグラビル併用薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Elvitegravir Combination Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:104
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、エルビテグラビル併用薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。エルビテグラビル併用薬の種類別市場規模(エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド併用薬、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビル併用薬)、用途別市場規模(病院、クリニック、ドラッグセンター、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Gilead Sciences、Bristol-Myers Squibb、Janssen Pharmaceutica (Johnson & Johnson)、Biocon Limited、Flamingo Pharmaceuticals Limited、IPCA Laboratories、Medisist Pharma、Affine Formulations Limited
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:エルビテグラビル/コビシスタット/エムトリシタビン/テノホビルアラフェナミド併用薬、エルビテグラビル/コビシスタット/エムトリシタビン/テノホビル併用薬
・用途別分析2016年-2026年:病院、クリニック、ドラッグセンター、その他
・エルビテグラビル併用薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・エルビテグラビル併用薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・エルビテグラビル併用薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・エルビテグラビル併用薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・エルビテグラビル併用薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Elvitegravir Combination Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Elvitegravir Combination Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Elvitegravir Combination Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Elvitegravir Combination Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug

Market segment by Application, can be divided into
Hospital
Clinic
Drug Center
Other

Market segment by players, this report covers
Gilead Sciences
Bristol-Myers Squibb
Janssen Pharmaceutica (Johnson & Johnson)
Biocon Limited
Flamingo Pharmaceuticals Limited
IPCA Laboratories
Medisist Pharma
Affine Formulations Limited

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Elvitegravir Combination Drugs
1.2 Classification of Elvitegravir Combination Drugs by Type
1.2.1 Overview: Global Elvitegravir Combination Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Elvitegravir Combination Drugs Revenue Market Share by Type in 2020
1.2.3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Combination Drug
1.2.4 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Combination Drug
1.3 Global Elvitegravir Combination Drugs Market by Application
1.3.1 Overview: Global Elvitegravir Combination Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global Elvitegravir Combination Drugs Market Size & Forecast
1.5 Global Elvitegravir Combination Drugs Market Size and Forecast by Region
1.5.1 Global Elvitegravir Combination Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Elvitegravir Combination Drugs Market Size by Region, (2016-2021)
1.5.3 North America Elvitegravir Combination Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Elvitegravir Combination Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Elvitegravir Combination Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Elvitegravir Combination Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Elvitegravir Combination Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Elvitegravir Combination Drugs Market Drivers
1.6.2 Elvitegravir Combination Drugs Market Restraints
1.6.3 Elvitegravir Combination Drugs Trends Analysis
2 Company Profiles
2.1 Gilead Sciences
2.1.1 Gilead Sciences Details
2.1.2 Gilead Sciences Major Business
2.1.3 Gilead Sciences Elvitegravir Combination Drugs Product and Solutions
2.1.4 Gilead Sciences Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Gilead Sciences Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Elvitegravir Combination Drugs Product and Solutions
2.2.4 Bristol-Myers Squibb Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Janssen Pharmaceutica (Johnson & Johnson)
2.3.1 Janssen Pharmaceutica (Johnson & Johnson) Details
2.3.2 Janssen Pharmaceutica (Johnson & Johnson) Major Business
2.3.3 Janssen Pharmaceutica (Johnson & Johnson) Elvitegravir Combination Drugs Product and Solutions
2.3.4 Janssen Pharmaceutica (Johnson & Johnson) Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Janssen Pharmaceutica (Johnson & Johnson) Recent Developments and Future Plans
2.4 Biocon Limited
2.4.1 Biocon Limited Details
2.4.2 Biocon Limited Major Business
2.4.3 Biocon Limited Elvitegravir Combination Drugs Product and Solutions
2.4.4 Biocon Limited Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Biocon Limited Recent Developments and Future Plans
2.5 Flamingo Pharmaceuticals Limited
2.5.1 Flamingo Pharmaceuticals Limited Details
2.5.2 Flamingo Pharmaceuticals Limited Major Business
2.5.3 Flamingo Pharmaceuticals Limited Elvitegravir Combination Drugs Product and Solutions
2.5.4 Flamingo Pharmaceuticals Limited Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Flamingo Pharmaceuticals Limited Recent Developments and Future Plans
2.6 IPCA Laboratories
2.6.1 IPCA Laboratories Details
2.6.2 IPCA Laboratories Major Business
2.6.3 IPCA Laboratories Elvitegravir Combination Drugs Product and Solutions
2.6.4 IPCA Laboratories Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 IPCA Laboratories Recent Developments and Future Plans
2.7 Medisist Pharma
2.7.1 Medisist Pharma Details
2.7.2 Medisist Pharma Major Business
2.7.3 Medisist Pharma Elvitegravir Combination Drugs Product and Solutions
2.7.4 Medisist Pharma Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Medisist Pharma Recent Developments and Future Plans
2.8 Affine Formulations Limited
2.8.1 Affine Formulations Limited Details
2.8.2 Affine Formulations Limited Major Business
2.8.3 Affine Formulations Limited Elvitegravir Combination Drugs Product and Solutions
2.8.4 Affine Formulations Limited Elvitegravir Combination Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Affine Formulations Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Elvitegravir Combination Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Elvitegravir Combination Drugs Players Market Share
3.2.2 Top 10 Elvitegravir Combination Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Elvitegravir Combination Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Elvitegravir Combination Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Elvitegravir Combination Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Elvitegravir Combination Drugs Revenue Market Share by Application (2016-2021)
5.2 Elvitegravir Combination Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Elvitegravir Combination Drugs Revenue by Type (2016-2026)
6.2 North America Elvitegravir Combination Drugs Revenue by Application (2016-2026)
6.3 North America Elvitegravir Combination Drugs Market Size by Country
6.3.1 North America Elvitegravir Combination Drugs Revenue by Country (2016-2026)
6.3.2 United States Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Elvitegravir Combination Drugs Revenue by Type (2016-2026)
7.2 Europe Elvitegravir Combination Drugs Revenue by Application (2016-2026)
7.3 Europe Elvitegravir Combination Drugs Market Size by Country
7.3.1 Europe Elvitegravir Combination Drugs Revenue by Country (2016-2026)
7.3.2 Germany Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
7.3.3 France Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Elvitegravir Combination Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Elvitegravir Combination Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Elvitegravir Combination Drugs Market Size by Region
8.3.1 Asia-Pacific Elvitegravir Combination Drugs Revenue by Region (2016-2026)
8.3.2 China Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8.3.5 India Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Elvitegravir Combination Drugs Revenue by Type (2016-2026)
9.2 South America Elvitegravir Combination Drugs Revenue by Application (2016-2026)
9.3 South America Elvitegravir Combination Drugs Market Size by Country
9.3.1 South America Elvitegravir Combination Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Elvitegravir Combination Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Elvitegravir Combination Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Elvitegravir Combination Drugs Market Size by Country
10.3.1 Middle East & Africa Elvitegravir Combination Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Elvitegravir Combination Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Gilead Sciences、Bristol-Myers Squibb、Janssen Pharmaceutica (Johnson & Johnson)、Biocon Limited、Flamingo Pharmaceuticals Limited、IPCA Laboratories、Medisist Pharma、Affine Formulations Limited

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のエルビテグラビル併用薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Elvitegravir Combination Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。